The opioid crisis: A view from NIDA

Size: px
Start display at page:

Download "The opioid crisis: A view from NIDA"

Transcription

1 The opioid crisis: A view from NIDA National Institute on Drug Abuse Bringing the full power of of science to bear to bear on drug on drug abuse abuse and addiction and addiction Nora D. Volkow, M.D. Director National Institute on Drug Abuse Carlos Blanco, M.D., Ph.D. Director, Division of Epidemiology, Services and Prevention National Institute on Drug Abuse Science = Solutions

2 Develop a Learning Health Care System Using Clinical Practice to Generate Meaningful Research Questions Ensuring that Research Findings are Applied to Practice

3 Addiction is a Disease of the Brain EXECUTIVE FUNCTION/ INHIBITORY CONTROL OFC MOTIVATION/ DRIVE PFC ACG SCC NAcc Amyg VP Hipp MEMORY/ LEARNING REWARD

4 1. Reward Circuit NAcc VP REWARD Drugs of Abuse Engage Systems in the Reward Pathways of the Brain

5 2. Memory circuit Hipp Amyg MEMORY/ LEARNING People, Place and Things

6 3. Motivation & Executive Control Circuits Dopamine is also associated with motivation and executive function via regulation of frontal activity. EXECUTIVE FUNCTION PFC INHIBITORY CONTROL ACG OFC SCC MOTIVATION/ DRIVE

7 The fine balance in connections that normally exists between brain areas active in reward, learning and memory, motivation and inhibitory control EXECUTIVE FUNCTION INHIBITORY CONTROL PFC MOTIVATION/ DRIVE ACG OFC SCC NAcc Amyg Hipp VP REWARD MEMORY/ LEARNING Becomes severely disrupted in ADDICTION

8 ADDICTIONS as diseases of Gene-Environment-Development Addictions are common, developmental brain diseases expressed as compulsive behavior through continued use of a drug despite negative consequences: Onset depends on many intrinsic and extrinsic factors. Biology Genes/Development Environment DRUG/ALCOHOL Brain Mechanisms Addiction

9 RISK FACTORS FOR SUBSTANCE USE DISORDER Family History Childhood Disturbed FamilyChildhood of SUD Sexual Abuse Environment Parental Loss Impulsivity Low Early-Onset Early-Onset Self-Esteem Anxiety SU Social Deviance Low Education Ever Divorced Low Social Marital Support Problems in DRUG AVAILABILITY History of Trauma Low Religious Services History of SUD Stressful Life Events SUD LAST YEAR Psychiatric Comorbidity Social Deviance Social Deviance

10 Natural course of recovery for four substances Lopez-Quintero et al.,

11 Percent Switching Addictions? New Onset SUD With SUD Remission Did Not Remit P<.001 Data are from NESARC Waves 1 and 2 Blanco et al., JAMA Psychiatry

12 Develop a Learning Health Care System Using Clinical Practice to Generate Meaningful Research Questions Ensuring that Research Findings are Applied to Practice

13 Key Drug Abuse Public Health Crisis The NEW ENGLAND JOURNAL of MEDICINE REVIEW ARTICLE Relationship between Nonmedical Prescription-Opioid Use and Heroin use Wilson M. Compton, M.D., M.P.E., Christopher M. Jones, Pharm.D, M.P.H. and Grant T. Baldwin, Ph.D., M.P.H. January 14, 2016 Opioid Drug Abuse: Prescription Opioids AND Heroin JAMA The Journal of the American Medical Association October 13, 2015 Original Investigation Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, Beth Han, MD, PhD; Wilson M. Compton, MD, MPE; Christopher M. Jones, PharmD, MPH; Rong Cai, MS

14 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 Overdose Deaths Continue to Increase 16,849 63,632 52,404 47,055 Source: Data Brief 294. NCHS, National Vital Statistics System, Mortality

15 Changing Outcomes:Fentanyl Overtakes Heroin as Leading Cause of U.S. Drug Death JOSH KATZ SEPT. 2, 2017 Drug overdoses killed roughly 64,000 people in USA in 2016; 22% rise over Fentanyls are changing equation: Death rate in Maryland last year outpaced that in Kentucky and Maine. Estimate U.S. Drug Deaths in 2016 Graph from NY Times Article based on CDC MMWR Report 2017

16 Rising rates of HCV Counties Deemed Highly Vulnerable to Rapid Dissemination of HCV or HIV 3,000 2,500 2,000 1,500 1, Number of cases3,500 ~31,000 new HCV infections in :1 male: female ratio, predominantly white National Notifiable Diseases Surveillance System (NNDSS) HIV (and Hepatitis C) Outbreak Linked to Oxymorphone Injection Use in Indiana, 2015 Peters et al. The New England Journal of Medicine 2016;375: Source: Van Handel et al, JAIDS 2016

17 Science = Solutions : Opioid Use and Misuse During Pregnancy Increasing NICU Admissions for Neonatal Abstinence Syndrome NAS (per 1000 Admissions) Increasing Costs for Neonatal Exposure Source: Tolia VN, Patrick SW, et al., NEJM 2015;372: Source: Winkelman TNA, Villapiano N, Kozhimannil KB, Davis MM, Patrick SM.. Pediatrics. 2018;141(4):e

18 Percent Overlap of Benzodiazepines and Opioids Opioid Analgesic ED Visits and OD Deaths Involving Benzodiazepines & Benzodiazepine ED Visits and OD Deaths Involving Opioids AAPC = 1.5% (95% CI 0.8%-2.2%) AAPC = 8.4% (95% CI 7.1%-9.7%) AAPC = 3.0% (95% CI 1.3%-4.8%) AAPC = 4.5% (95% CI2.4%-6.6%) 0 Deaths Involving Benzodiazepines ED Visits Involving Benzodiazepines Deaths Involving Opioid Analgesics ED Visits Opioid Analgesics Opioid Analgesics Benzodiazepines Source: CM Jones, JK McAninch. American Journal of Preventive Medicine 2015;49:

19 Heroin Market Has Changed: Heroin Price Has Been Lower in Recent Years $3,500 $3,000 $2,500 $2,000 $1,500 $1,000 $500 $- "Retail" Price Per Pure Gram Source: National Drug Control Strategy--Data Supplement

20 High Levels of Opioid Prescriptions have Facilitated Diversion & Contributed to Overdose Deaths Near Tripling of Opioid Prescriptions from U.S. Retail Pharmacies, Total Rx Opioid Tablets Dispensed in Retail Pharmacies in the USA: ,972,304, ,606,882,755 Source: Jones CM, et al. JAMA Internal Medicine 2016: doi: /jamainternmed IMS Health, Vector One : National, IMS Health, National Prescription Audit,

21 Prescriptions (millions) OPIOID MME IN BILLIONS Opioid Prescriptions Opioid morphine milligram equivalents (MME) dispensed fell by over 15% from Opioids Hydrocodone Oxycodone IMS Health, U.S. Outpatient Retail Setting

22 NIH OPIOID RESEARCH INITIATIVE Using Research to End the Opioid Crisis PREVENTION OUD PAIN MANAGEMENT Safe, more effective strategies OPIOID ADDICTION TREATMENT New and innovative medications and technologies OVERDOSE REVERSAL Interventions to reduce mortality and link to treatment

23 1. Inadequate Pain Treatment as a Driver 91.8 million adults used prescription opioids (37.8% of the U.S. adult population) 11.5 million adults misused prescription opioids (4.7% of the U.S. adult population) 1.9 million adults had prescription opioid use disorders (0.8% of the U.S. adult population) relieve physical pain relax or relieve tension experiment get high or feel good help with sleep 11.2 help with emotions or feelings 66.3 increase/decrease effects of other drugs hooked or have to misuse other reason Source: Han, Compton, et al. Annals of Internal Medicine 2017 (epub Aug 1, 2017)

24 2. Direct Overdose Intervention Naloxone Distribution for opioid overdose victims. The potential for direct intervention to save lives. Note the April 3, 2014 FDA approval of the naloxone auto-injector (called Evzio ) Naloxone Nasal Spray Development Needle-free, unit-dose, ready-to-use opioid overdose antidote. Adapt Pharma NARCAN nasal spray APPROVED BY FDA, November 18, Science = Solutions

25 3. Medication Diversion: Prevention/brief interventions People misusing analgesics Directly & Indirectly obtain them by prescription Source where pain relievers obtained for most recent misuse Prescription 36% Other 1 Friend/ Relative 5 87% Their Prescription Other 3% 1 Their Friend/Relative Source: SAMHSA, 2015 National Survey on Drug Use and Health.

26 Doctors (and other clinicians) Need to Know What Prescriptions Have Been Given to Their Patients By Other Practitioners This information should be: 1. included in the patients electronic health care records 2. accessible through a Prescription Drug Monitoring Program (PDMP) that provides immediate information

27 Opioid Effect 4. OUD Cascade of Care Medication Assisted Treatment (MAT) OUD Cascade of Care in USA Log Dose Full Agonist (Methadone: Daily Dosing) Partial Agonist (Buprenorphine: 3-4X week) Antagonist (Naltrexone: ER 1 month) DECREASES: Opioid use Opioid-related overdose deaths Criminal activity Infectious disease transmission INCREASES Social functioning Retention in treatment But MAT is highly underutilized! Relapse rates are very high! Current estimates Treatment gap 90% goal Williams AR, Nunes E, Olfson M. Health Affairs Blog, 2017.

28 Accessing Medications Can Save Lives Opioid Agonist Treatments Decreased Heroin OD Deaths Baltimore, Maryland, Heroin overdoses Buprenorphine patients Methadone patients Schwartz RP et al., Am J Public Health Science = Solutions

29 In 48 states and D.C., Opioid Use Disorder Rates Exceed Buprenorphine Treatment Capacity Jones C et al., Am J Public Health Medications are Underused 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% In 2014, only 25% of opioid admissions had treatment plans that included receiving medications. 100% % Treatment Programs Offering FDA-approved SUD Medications 25% 9% 17% 9% 16% 19% 25% MAT 75% No MAT Treatment Episode Data Set (TEDS): Knudsen et al., J Addict Med 2011

30

31 Develop a Learning Health Care System Using Clinical Practice to Generate Meaningful Research Questions Ensuring that Research Findings are Applied to Practice

32 Why is an LHS important? Knowing is not enough; we must apply. Willing is not enough; we must do. Goethe

33 What is an LHS? According to the National Academy of Medicine, one that uses: Science and Informatics Patient-Clinician Partnerships Incentives and Culture To enable continuous real-time improvement in: Effectiveness Efficiency of care Source: National Academy of Medicine, Best Care at Lower Cost, 2013

34 In reality A Feedback Loop from Research to Practice Role of Practice: Question generation Role of Research: Find generalizable answers Practice and Research defined broadly

35 Traditional View of Innovation Rogers E, Diffusion of Innovations, 1962

36 LHS View of Innovation Green et al., Ann Int Med, 2002;157:

37 Summary Addictions can be prevented and treated. Complex biological, developmental and social aspects of substance abuse and addiction suggest multipronged responses. Science provides clues and is essential in planning responses. There is a need to develop a learning healthcare system

38 Develop a Learning Health Care System Using Clinical Practice to Generate Meaningful Research Questions Ensuring that Research Findings are Applied to Practice

Advancing Addiction Science to Address the Opioid Crisis

Advancing Addiction Science to Address the Opioid Crisis Advancing Addiction Science to Address the Opioid Crisis National Institute on Drug Abuse Bringing the full power of science to bear on drug abuse and addiction Nora D. Volkow, M.D. Director National Institute

More information

Advancing Addiction Science to Address the Opioid Crisis

Advancing Addiction Science to Address the Opioid Crisis Advancing Addiction Science to Address the Opioid Crisis National Institute on Drug Abuse Bringing the full power of science to bear on drug abuse and addiction Nora D. Volkow, M.D. Director National Institute

More information

Changing Federal Health Care Policies

Changing Federal Health Care Policies Changing Federal Health Care Policies A view from NIDA Carlos Blanco, M.D., Ph.D. Director Division of Epidemiology, Services and Prevention National Institute on Drug Abuse Advancing Addiction Science

More information

Science = Solutions. Carlos Blanco, M.D., Ph.D. Director, Division of Epidemiology, Services and Prevention Research National Institute on Drug Abuse

Science = Solutions. Carlos Blanco, M.D., Ph.D. Director, Division of Epidemiology, Services and Prevention Research National Institute on Drug Abuse Advancing Addiction Science Science = Solutions Carlos Blanco, M.D., Ph.D. Director, Division of Epidemiology, Services and Prevention Research National Institute on Drug Abuse John Smith James Smith Ann

More information

National Academies of Sciences, Engineering, and Medicine Forum on Neuroscience and Nervous System Disorders

National Academies of Sciences, Engineering, and Medicine Forum on Neuroscience and Nervous System Disorders National Academies of Sciences, Engineering, and Medicine Forum on Neuroscience and Nervous System Disorders Workshop: Advancing Therapeutic Development for Pain and Opioid Use Disorders through Public-Private

More information

Chronic Pain in Women and its Relationship to Opioid Addiction

Chronic Pain in Women and its Relationship to Opioid Addiction Chronic Pain in Women and its Relationship to Opioid Addiction Advancing Addiction Science Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse OPIOIDS are Powerful Analgesics

More information

The Opioid Epidemic: HHS Response

The Opioid Epidemic: HHS Response The Opioid Epidemic: HHS Response Christopher M. Jones, PharmD, MPH Acting Associate Deputy Assistant Secretary (Science and Data Policy) Office of the Assistant Secretary for Planning and Evaluation U.S.

More information

NIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV. Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse

NIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV. Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse NIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse Virtually All of the U.S. Have Increased Drug Overdoses:

More information

SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC

SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC SC MAT ACCESS Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC Overdose Death Rates from Opiates Most important sign of a

More information

Responding to the Opioid Morbidity and Mortality Crisis

Responding to the Opioid Morbidity and Mortality Crisis Session ID: 17 16 Disclosures of Interests: Wilson M. Compton, MD, MPE Long-Term Stock Equity (unrelated to the presentation): 3M Company (under $1,) General Electric Corporation (under $1,) Pfizer, Inc.

More information

Innovative Research and the Opioid Epidemic: Are We Closer to Finding Solutions? October 13, :00 3:00 p.m. ET Webinar

Innovative Research and the Opioid Epidemic: Are We Closer to Finding Solutions? October 13, :00 3:00 p.m. ET Webinar Innovative Research and the Opioid Epidemic: Are We Closer to Finding Solutions? October 13, 2017 2:00 3:00 p.m. ET Webinar The Role of Research in Finding Solutions to the Opioid Epidemic Nora D. Volkow,

More information

Mark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC

Mark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC Opioid Use Disorders and Their Treatment Mark Edlund, MD, PhD RTI International Photo courtesy of The Herb Museum, Vancouver, BC Acknowledgements Funded by NIDA R01 DA022560-01 NIDA R01 DA034627 NIDA R01

More information

Strategies to Manage The Opioid Crisis

Strategies to Manage The Opioid Crisis Strategies to Manage The Opioid Crisis Matt Feehery, LCDC Senior Vice President & CEO PaRC (Prevention & Recovery Center) Behavioral Health Services February 1, 2018 A Pill for Your Pain But my doctor

More information

Mental Health and Behavioral Health

Mental Health and Behavioral Health Mental Health and Behavioral Health mpfc (AC) Insula Thal DS GP VS VS VTA VTA Hippo OFC Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Advancing Addiction Science Behavioral

More information

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand

More information

HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder

HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder Brett Giroir, U.S. Department of Health and Human Services Join the conversation at #OUDTreatment #EndTheStigma Expanding

More information

Aetna s Initiative on the Opioid Epidemic

Aetna s Initiative on the Opioid Epidemic Aetna s Initiative on the Opioid Epidemic Christopher James D.O., M.P.H. Medical Director, BH- Mid-Atlantic Territory (JamesC1@aetna.com) July 23, 2017 HHS Data on Epidemic Every Day in the U.S. More than

More information

Opioid Harm Reduction

Opioid Harm Reduction Opioid Harm Reduction Lucas G. Hill, PharmD Clinical Assistant Professor, The University of Texas at Austin College of Pharmacy Clinical Pharmacist, CommUnityCare FQHCs Director, Operation Naloxone Mark

More information

Policy and Political Dynamics of the Opioid Addiction Crisis in the United States

Policy and Political Dynamics of the Opioid Addiction Crisis in the United States Policy and Political Dynamics of the Opioid Addiction Crisis in the United States Mark W. Parrino, M.P.A. July 21, 2018 15 th Annual Midwest Conference on Problem Gambling and Substance Abuse Hilton Kansas

More information

Prescription Opioids

Prescription Opioids What are prescription opioids? Prescription Opioids Opioids are a class of drugs naturally found in the opium poppy plant. Some prescription opioids are made from the plant directly, and others are made

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

The Science of Addiction: Prescription Opioid Abuse. Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse

The Science of Addiction: Prescription Opioid Abuse. Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse The Science of Addiction: Prescription Opioid Abuse Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse Key Points: 1. Prescription opioid abuse is a major problem in USA

More information

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

Opioid Treatment in North Carolina SEPTEMBER 13, 2016 Opioid Treatment in North Carolina SEPTEMBER 13, 2016 Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: 2007 Source Where Respondent Obtained

More information

Opioid Abuse and Prescribing. Dr. Mitchell Mutter Director of Special Projects

Opioid Abuse and Prescribing. Dr. Mitchell Mutter Director of Special Projects Opioid Abuse and Prescribing Dr. Mitchell Mutter Director of Special Projects Auburn University February 22, 2019 Disclosure Statement of Financial Interest I, Mitchell Mutter, DO NOT have a financial

More information

Science = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse

Science = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Science = Solutions For Substance Use Disorders and Infant Outcomes Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Science = Solutions Increased Opioid Mortality: Greater

More information

Policy Implications of the Neurobiology of Addiction

Policy Implications of the Neurobiology of Addiction Policy Implications of the Neurobiology of Addiction Facilitator: Jay Butler, MD, President of ASTHO, Chief Medical Officer Alaska Department of Health and Social Services Director, Alaska Division of

More information

Opioid Overview Admiral Brett P. Giroir, M.D.

Opioid Overview Admiral Brett P. Giroir, M.D. A S S I S TA N T S E C R E TA RY F O R H E A LT H Opioid Overview Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioid Policy @HHS_ASH August 20, 2018 SUBSTANCE ABUSE

More information

Heroin. What is heroin?

Heroin. What is heroin? What is heroin? Heroin Heroin is an opioid drug made from morphine, a natural substance taken from the seed pod of the Asian opium poppy plant. Heroin can be a white or brown powder, or a black sticky

More information

Opioid Use and Other Trends

Opioid Use and Other Trends Opioid Use and Other Trends National Overview Across the nation communities are struggling with a devastating increase in the number of people misusing opioid drugs, leading many to identify the current

More information

ADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians

ADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians ADDRESSING THE OPIOID EPIDEMIC Joint principles of the following organizations representing front-line physicians American Academy of Family Physicians American Academy of Pediatrics American College of

More information

U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs

U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs Michelle Van Handel, MPH Health Scientist National Center for HIV/AIDS, Viral Hepatitis, STDs and

More information

Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story

Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story Sarah Sharfstein Kawasaki, MD Director of Addictions Services, Pennsylvania Psychiatric

More information

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction

More information

National Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic

National Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic National Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioids and Mental Health Policy @HHS_ASH

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Noel Schenk MD. Davis Behavioral Health

Noel Schenk MD. Davis Behavioral Health Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by

More information

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted

More information

Opioid Review and MAT Clinic CDC Guidelines

Opioid Review and MAT Clinic CDC Guidelines 1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are

More information

4/12/2018. Opioid Addiction and Prescribing. Disclosure Statement of Financial Interest

4/12/2018. Opioid Addiction and Prescribing. Disclosure Statement of Financial Interest Opioid Addiction and Prescribing Mitchell Mutter, MD Director of Special Projects Nashville, TN April 12, 2018 Disclosure Statement of Financial Interest I, Mitchell Mutter, DO NOT have a financial interest/arrangement

More information

PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE

PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE September 20, 2013 Association of State and Territorial Health Officials Annual Meeting R. Gil Kerlikowske Director of National Drug Control Policy National

More information

Understanding and Combating the Heroin Epidemic

Understanding and Combating the Heroin Epidemic Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the

More information

MAT in the Corrections Setting

MAT in the Corrections Setting MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on

More information

Idaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D.

Idaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D. Idaho DUR Board Meeting Minutes Date: January 25, 2018 Time: 9am-12:00pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: David Agler, M.D. Committee Member

More information

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE

More information

The Epidemiology of Opioid Abuse. Thomas Dobbs, MD, MPH Mississippi State Department of Health

The Epidemiology of Opioid Abuse. Thomas Dobbs, MD, MPH Mississippi State Department of Health The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH Mississippi State Department of Health 1/12/2018 ACKNOWLEDGEMENTS DRUG ABUSE WORKING GROUP MISSISSIPPI STATE DEPARTMENT OF HEALTH Manuela Staneva,

More information

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative John W. McIlveen, Ph.D., LMHC, State Opioid Treatment Authority, Oregon Health Authority, Addictions and Mental Health Division

More information

Addressing the Opioid Epidemic in Tennessee

Addressing the Opioid Epidemic in Tennessee Addressing the Opioid Epidemic in Tennessee A Multidisciplinary Approach Melissa McPheeters, PhD, MPH Director, Informatics and Public Health Analytics 26 108 733 *Source: CDC References Centers for

More information

Division of Mental Health and Addiction Services

Division of Mental Health and Addiction Services Division of Mental Health and Addiction Services A DAM BUCON, LSW DMHAS Mission DMHAS, in partnership with consumers, family members, providers and other stakeholders, promotes wellness and recovery for

More information

Michael M. Miller, MD, FASAM, FAPA

Michael M. Miller, MD, FASAM, FAPA Michael M. Miller, MD, FASAM, FAPA mmiller@rogershospital.org Medical Director, Herrington Recovery Center (HRC) Rogers Memorial Hospital Oconomowoc, Wisconsin Vice Speaker Wisconsin Medical Society Clinical

More information

The Opioid Crisis in Kentucky. Doug Oyler, PharmD Director, Office of Opioid Safety UK HealthCare

The Opioid Crisis in Kentucky. Doug Oyler, PharmD Director, Office of Opioid Safety UK HealthCare The Opioid Crisis in Kentucky Doug Oyler, PharmD Director, Office of Opioid Safety UK HealthCare Discuss the role of opioid prescribing in creating and sustaining the crisis Describe components and initiatives

More information

The Prescription Opioid and Heroin Crisis

The Prescription Opioid and Heroin Crisis The Prescription Opioid and Heroin Crisis Dr. Rachel L. Levine Acting Secretary of Health and Physician General Professor of Pediatrics and Psychiatry Penn State College of Medicine Overdose deaths from

More information

Opioid Use in Youth. Amy Yule M.D. March 2,

Opioid Use in Youth. Amy Yule M.D. March 2, Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin

More information

Methadone and Naltrexone ER

Methadone and Naltrexone ER Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my

More information

SAMHSA/HHS: An Update on the Opioid Crisis

SAMHSA/HHS: An Update on the Opioid Crisis SAMHSA/HHS: An Update on the Opioid Crisis Elinore F. McCance-Katz, MD, PhD Assistant Secretary for Mental Health and Substance Use Substance Abuse and Mental Health Services Administration U.S. Department

More information

CDC s Efforts to End the Opioid Epidemic

CDC s Efforts to End the Opioid Epidemic Amy Insert Peeples, CIO Name MPA Here Deputy Director, National Center for Injury Prevention and Control NCSL Opioid Policy Fellows Kick Off CDC s Efforts to End the Opioid Epidemic The Epidemic in America

More information

From Opioid Overdose Prevention to Community Resilience CAPT Jeffrey Coady, Psy.D., ABPP SAMHSA Regional Administrator (Region 5)

From Opioid Overdose Prevention to Community Resilience CAPT Jeffrey Coady, Psy.D., ABPP SAMHSA Regional Administrator (Region 5) From Opioid Overdose Prevention to Community Resilience CAPT Jeffrey Coady, Psy.D., ABPP SAMHSA Regional Administrator (Region 5) Region 5 Fatherhood Initiative October 24, 2017 Today s Presentation Public

More information

Epidemiologic Data on Opioid Use: Changing Problems

Epidemiologic Data on Opioid Use: Changing Problems Epidemiologic Data on Opioid Use: Changing Problems 1 Goals 1 To bridge the pain world and addiction world 1. Pain and pain treatment a. Chronic pain affects an estimated 100 million Americans (1/3 of

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for

More information

Opioid Use Disorders &Medication Treatment

Opioid Use Disorders &Medication Treatment Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review

More information

Shawn A. Ryan, MD, MBA Assistant Professor, Dept. of Emergency Medicine, University of Cincinnati Chair of Quality & Patient Safety, Jewish

Shawn A. Ryan, MD, MBA Assistant Professor, Dept. of Emergency Medicine, University of Cincinnati Chair of Quality & Patient Safety, Jewish Shawn A. Ryan, MD, MBA Assistant Professor, Dept. of Emergency Medicine, University of Cincinnati Chair of Quality & Patient Safety, Jewish Hospital-Mercy Health Partners Addiction Specialist, BrightView

More information

Cannabis and Opioids in AANHPI David Kan, MD, DFASAM University of California, San Francisco

Cannabis and Opioids in AANHPI David Kan, MD, DFASAM University of California, San Francisco Substance Use in AANHPI Cannabis and Opioids in AANHPI David Kan, MD, DFASAM University of California, San Francisco In general: Lower rates of illegal drug use Binge Alcohol use Substance Use Disorder

More information

AGENDA U.S. SURGEON GENERAL, VIVEK MURTHY MD 2/5/2019

AGENDA U.S. SURGEON GENERAL, VIVEK MURTHY MD 2/5/2019 FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5

More information

U.S. SURGEON GENERAL, VIVEK MURTHY MD

U.S. SURGEON GENERAL, VIVEK MURTHY MD FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5

More information

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country Integrating Primary and Behavioral Health Care Through the Lens of Prevention July 14, 2016 New Orleans, Louisiana The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin

More information

People inject, sniff, snort, or smoke heroin. Some people mix heroin with crack cocaine, a practice called speedballing.

People inject, sniff, snort, or smoke heroin. Some people mix heroin with crack cocaine, a practice called speedballing. What is heroin? Heroin is an opioid drug made from morphine, a natural substance taken from the seed pod of the various opium poppy plants grown in Southeast and Southwest Asia, Mexico, and Colombia. Heroin

More information

The Opioid Crisis: What Can Physicians Do About It?

The Opioid Crisis: What Can Physicians Do About It? The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures

More information

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Clint Ross, PharmD, BCPP Clinical Pharmacy Specialist Psychiatry Residency Program Director Psychiatric Pharmacy Medical University

More information

Neurobiological Advances in Addiction Science: Implications For Prevention and Treatment Nora D. Volkow, M.D. Director

Neurobiological Advances in Addiction Science: Implications For Prevention and Treatment Nora D. Volkow, M.D. Director Neurobiological Advances in Addiction Science: Implications For Prevention and Treatment Nora D. Volkow, M.D. Director @NIDAnews Drugs and Natural Rewards ACTIVATE Dopamine in Reward Regions % of Basal

More information

DHCS Tribal MAT Project

DHCS Tribal MAT Project DHCS Tribal MAT Project Melissa Eidman & Valentine Antony California Consortium for Urban Indian Health August 2018 CaliforniaConsortiumforUrbanIndianHealth CCUIH StrengtheningTheOrganizationsThatStrengthenOurCommunities

More information

Naloxone Statewide Standing Order. Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties

Naloxone Statewide Standing Order. Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties Naloxone Statewide Standing Order Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties Objectives Review the US & NC trends on opioid overdose Understand key

More information

Opioid Epidemic as it Relates to Counties

Opioid Epidemic as it Relates to Counties 89 TH ANNUAL WEST TEXAS COUNTY JUDGES AND COMMISSIONERS ASSOCIATION CONFERENCE Wednesday, April 25, 2018 11:05 11:55 a.m. Opioid Epidemic as it Relates to Counties Ms. Jessica Cance Agency Analytics Unit

More information

Drug Abuse & Addiction Research: Progress, Priorities, & Challenges

Drug Abuse & Addiction Research: Progress, Priorities, & Challenges Drug Abuse & Addiction Research: Progress, Priorities, & Challenges National Institute on Drug Abuse Bringing the full power of science to bear on drug abuse and addiction Nora D. Volkow, M.D. Director

More information

The Role of the Emergency Department in the Opioid Epidemic. Scott G. Weiner, MD, MPH Department of Emergency Medicine Brigham and Women s Hospital

The Role of the Emergency Department in the Opioid Epidemic. Scott G. Weiner, MD, MPH Department of Emergency Medicine Brigham and Women s Hospital The Role of the Emergency Department in the Opioid Epidemic Scott G. Weiner, MD, MPH Department of Emergency Medicine Brigham and Women s Hospital Disclosures Treasurer, Massachusetts College of Emergency

More information

The Population is Abusing Drugs, but are Drugs Abusing Insurance?

The Population is Abusing Drugs, but are Drugs Abusing Insurance? Image licensed from Shutterstock The Population is Abusing Drugs, but are Drugs Abusing Insurance? 01/30/2018 Gina C. Guzman, MD, DBIM, FALU, FLMI, VP and Chief Medical Director Tim Morant, FSA, MAAA,

More information

The Science of Drug Addiction: Implications for Clinical Practice

The Science of Drug Addiction: Implications for Clinical Practice The Science of Drug Addiction: Implications for Clinical Practice Jack B. Stein, Ph.D. Director Office of Science Policy and Communications National Institute on Drug Abuse National Institutes of Health

More information

Prescription Opioid Policies (22 March 2016)

Prescription Opioid Policies (22 March 2016) Prescription Opioid Policies (22 March 2016) Prescription opioid misuse and abuse has become problematic in the United States and internationally in economically developed countries. Increased use of opioids

More information

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016 What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)

More information

Research Priorities of NIDA s Medications Development Program

Research Priorities of NIDA s Medications Development Program Research Priorities of NIDA s Medications Development Program Iván D. Montoya, M.D., M.P.H. Deputy Director, Division of Therapeutics and Medical Consequences NIDA No Disclosures NIDA Medications Development

More information

Care in the Face of the Opioid Epidemic: How Yale University and Yale New Haven Hospital are Reaching Underserved Communities

Care in the Face of the Opioid Epidemic: How Yale University and Yale New Haven Hospital are Reaching Underserved Communities Care in the Face of the Opioid Epidemic: How Yale University and Yale New Haven Hospital are Reaching Underserved Communities Jeanette M. Tetrault, MD FACP FASAM Associate Professor of Medicine Program

More information

Addressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain

Addressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain Addressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain Ajay D. Wasan, MD, MSc Professor of Anesthesiology and Psychiatry Vice Chair for Pain Medicine, Department of Anesthesiology University

More information

The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017

The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017 The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017 The Mississippi Drug Abuse Project, Mississippi State Department of Health Working Group Manuela Staneva, MPH, Project Epidemiologist Meg

More information

Addiction as a Neuropsychiatric Medical Condition

Addiction as a Neuropsychiatric Medical Condition Addiction as a Neuropsychiatric Medical Condition Wilson M. Compton, M.D., M.P.E. Director, Division of Epidemiology, Services and Prevention Research National Institute on Drug Abuse 5 November 2009 Summary

More information

Use of Suboxone and Other Treatment Modalities: Myths, Facts & Tips for Better Outcomes

Use of Suboxone and Other Treatment Modalities: Myths, Facts & Tips for Better Outcomes Use of Suboxone and Other Treatment Modalities: Myths, Facts & Tips for Better Outcomes MPHP Prescribers Summit 2018 Gulfport, MS March 13, 2018 Scott Hambleton, MD, DFASAM Medical Director, MRO Mississippi

More information

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017 Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial

More information

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South

More information

Aligning Market Objectives and Policy for National Public Health

Aligning Market Objectives and Policy for National Public Health Abuse-Deterrent Formulations Summit March 7, 2017 Alexandria, Virginia Aligning Market Objectives and Policy for National Public Health Shruti Kulkarni, Esq. Outside Counsel Twitter: @claad_coalition CLAAD

More information

Opioid Prescription and Illicit Drug Overdoses: On the Rise

Opioid Prescription and Illicit Drug Overdoses: On the Rise Opioid Prescription and Illicit Drug Overdoses: On the Rise Cindy Haynes, MSA-PA, CHES Chronic Pain Program Coordinator Northern Piedmont Community Care Duke Division of Community Health Objectives Define

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: July 20, 2017 Time: 9am-12:30pm Location: Holiday Inn Boise Airport 2970 West Elder Street, Boise, Idaho, 83705 Moderator: David Agler, M.D. Committee Member Present:

More information

Brain Health and Opioid Abuse

Brain Health and Opioid Abuse 2018 Statewide Tribal Opioid Summit Brain Health and Opioid Abuse Healing From Opiate Addiction Requires Comprehensive Approaches Psychological, Socio-Cultural, and Biological Donald R. Vereen, Jr., M.D.,

More information

The Challenge of Treating Pain

The Challenge of Treating Pain FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and

More information

The Opiate Crisis 4/6/18. April 9, Words are important. If you want to care for something, you call it a flower.

The Opiate Crisis 4/6/18. April 9, Words are important. If you want to care for something, you call it a flower. The Opiate Crisis Presented by Dr. Anahi Ortiz Franklin County Coroner April 9, 2018 Words are important. If you want to care for something, you call it a flower. If you want to kill something, you call

More information

Lisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR

Lisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR Lisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR 1 1. Skin disorders, including cysts, acne, and dermatitis. 2. Joint disorders, including osteoarthritis. 3. Back problems. Source: Mayo

More information

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director

More information

CDC Guideline for Prescribing Opioids for Chronic Pain

CDC Guideline for Prescribing Opioids for Chronic Pain National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug

More information

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Svetla Slavova, PhD Sara LaMantia, MS Terry Bunn, PhD Tracey Corey, MD 2016 Safe States Annual Meeting April 13, 2016, Albuquerque,

More information

Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids

Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids Richard C. Dart, MD, PhD Executive Director, RADARS System Professor, University of Colorado Competing

More information

Addictions 101: Understanding, Recognizing, and Treating the Disease State!

Addictions 101: Understanding, Recognizing, and Treating the Disease State! Addictions 101: Understanding, Recognizing, and Treating the Disease State! www.overdosefreepa.org Criminal Justice Personnel Curricula Core Component 1 2014, Overdose Prevention Coalition! The OverdoseFreePA

More information

Safe Practices and Action Items

Safe Practices and Action Items Safe Practices and Action Items Karen F Marlowe, Pharm D, BCPS Certified Pain Educator Auburn University Harrison School of Pharmacy University of South Alabama School of Medicine Case Study A 58 year

More information

7/17/2017. FSHP 2017 ANNUAL MEETING Nothing to disclose. Opioid Overuse: National Epidemic. Opioid Epidemic: CDC Data

7/17/2017. FSHP 2017 ANNUAL MEETING Nothing to disclose. Opioid Overuse: National Epidemic. Opioid Epidemic: CDC Data FSHP Disclosure Nothing to disclose Opioid Utilization and Overdose Katie Neff-Golub, PharmD, BCGP, CPh CJ1 Objectives Gain understanding of the opioid overuse epidemic Review the role of opioid medications

More information